Vanda Pharmaceuticals (VNDA) Income from Continuing Operations (2010 - 2026)
Vanda Pharmaceuticals recorded quarterly Income from Continuing Operations of 48524000.0 in Q1 2026, up 65.64% quarter-over-quarter from 141229000.0 in Q4 2025, and down 64.52% year-over-year from 136770532.87 in Q1 2025.
Vanda Pharmaceuticals' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 48524000.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations fell 64.52% year-over-year to 48524000.0; the TTM figure through Mar 2026 stood at 239530000.0 (down 441.53% YoY), while the FY2025 annual figure was 220474000.0, down 1066.53% from the prior year.
- Income from Continuing Operations came in at 48524000.0 for Q1 2026 at Vanda Pharmaceuticals, up from 141229000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 6861000.0 in Q4 2022 to a low of 141229000.0 in Q4 2025.
- A 5-year average of 16422235.29 and a median of 4518000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Across the five-year window, Income from Continuing Operations jumped 150.2% in 2023 and tumbled 4000.73% in 2024, its largest moves.
- Vanda Pharmaceuticals' Income from Continuing Operations stood at 6861000.0 in 2022, then tumbled by 134.85% to 2391000.0 in 2023, then plunged by 103.93% to 4876000.0 in 2024, then tumbled by 2796.41% to 141229000.0 in 2025, then surged by 65.64% to 48524000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 48524000.0, 141229000.0, and 22590000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -8.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.40 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Vanda Pharmaceuticals | 379.35 Mn | 177.04 Mn | 48.56 Mn | -48.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -48.52 Mn |
| Dec 31, 2025 | -141.23 Mn |
| Sep 30, 2025 | -22.59 Mn |
| Jun 30, 2025 | -27.19 Mn |
| Mar 31, 2025 | -29.49 Mn |
| Dec 31, 2024 | -4.88 Mn |
| Sep 30, 2024 | -5.34 Mn |
| Jun 30, 2024 | -4.52 Mn |
| Mar 31, 2024 | -4.16 Mn |
| Dec 31, 2023 | -2.39 Mn |
| Sep 30, 2023 | 137,000.00 |
| Jun 30, 2023 | 1.49 Mn |
| Mar 31, 2023 | 3.23 Mn |
| Dec 31, 2022 | 6.86 Mn |
| Sep 30, 2022 | 3.26 Mn |
| Jun 30, 2022 | 2.59 Mn |
| Mar 31, 2022 | -6.43 Mn |
| Dec 31, 2021 | 7.08 Mn |
| Sep 30, 2021 | 7.77 Mn |
| Jun 30, 2021 | 9.65 Mn |
| Mar 31, 2021 | 8.65 Mn |
| Dec 31, 2020 | 8.21 Mn |
| Sep 30, 2020 | 5.95 Mn |
| Jun 30, 2020 | 8.69 Mn |
| Mar 31, 2020 | 486,000.00 |
| Dec 31, 2019 | 4.24 Mn |
| Sep 30, 2019 | 100.42 Mn |
| Jun 30, 2019 | 11.53 Mn |
| Mar 31, 2019 | -612,000.00 |
| Dec 31, 2018 | 10.38 Mn |
| Sep 30, 2018 | 7.16 Mn |
| Jun 30, 2018 | 4.61 Mn |
| Mar 31, 2018 | 3.07 Mn |
| Dec 31, 2017 | -1.84 Mn |
| Sep 30, 2017 | -4.55 Mn |
| Jun 30, 2017 | -1.53 Mn |
| Mar 31, 2017 | -7.65 Mn |
| Dec 31, 2016 | -500,000.00 |
| Sep 30, 2016 | -430,000.00 |
| Jun 30, 2016 | -4.62 Mn |
| Mar 31, 2016 | -12.36 Mn |
| Dec 31, 2015 | -14.89 Mn |
| Sep 30, 2015 | -9.54 Mn |
| Jun 30, 2015 | -5.46 Mn |
| Mar 31, 2015 | -10.29 Mn |
| Dec 31, 2014 | 69.69 Mn |
| Sep 30, 2014 | -1.45 Mn |
| Jun 30, 2014 | -21.58 Mn |
| Mar 31, 2014 | -26.53 Mn |
| Dec 31, 2013 | -7.62 Mn |
| Sep 30, 2013 | -5.38 Mn |
| Jun 30, 2013 | -3.38 Mn |
| Mar 31, 2013 | -4.52 Mn |
| Dec 31, 2012 | 20.34 Mn |
| Sep 30, 2012 | -5.33 Mn |
| Jun 30, 2012 | -8.01 Mn |
| Mar 31, 2012 | -7.96 Mn |
| Dec 31, 2011 | -5.52 Mn |
| Sep 30, 2011 | -3.07 Mn |
| Jun 30, 2011 | -1.34 Mn |
| Mar 31, 2011 | 136,000.00 |
| Dec 31, 2010 | 2.79 Mn |
| Sep 30, 2010 | 3.18 Mn |
| Jun 30, 2010 | 1.28 Mn |